Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

BACKGROUND: The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio. We aimed to investigate whether hypoxia-associated genes could b...

Descripción completa

Detalles Bibliográficos
Autores principales: Bibby, Becky A. S., Thiruthaneeswaran, Niluja, Yang, Lingjian, Pereira, Ronnie R., More, Elisabet, McArt, Darragh G., O’Reilly, Paul, Bristow, Robert G., Williams, Kaye J., Choudhury, Ananya, West, Catharine M. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247203/
https://www.ncbi.nlm.nih.gov/pubmed/34210300
http://dx.doi.org/10.1186/s12894-021-00856-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247203/
https://www.ncbi.nlm.nih.gov/pubmed/34210300
http://dx.doi.org/10.1186/s12894-021-00856-x

Ejemplares similares